Can novel therapeutics halt the amyloid cascade?
Niels D Prins¹, Pieter Jelle Visser¹,² and Philip Scheltens¹*

Abstract
The amyloid hypothesis provides a basis for the development of new therapeutic strategies in Alzheimer’s disease. Two large trials have recently been published. The first is a phase 2 study of passive immunotherapy with bapineuzumab, a humanized anti-Ab monoclonal antibody directed against the N-terminus of Ab. This trial showed no differences within dose cohorts on the primary efficacy analysis. Exploratory analyses showed potential treatment differences on cognitive and functional endpoints in study completers and apolipoprotein E ε4 noncarriers. A safety concern was the occurrence of reversible vasogenic edema. The second study is a phase 3 trial of tarenflurbil, a modulator of the activity of γ-secretase. Tarenflurbil had no beneficial effect on the primary or secondary outcomes. The tarenflurbil group had a small increase in frequency of dizziness, anemia, and infections. Possible explanations for the negative results of these trials may be related to the study design or the choice of dosage. However, it may also be that these negative findings reflect our still incomplete understanding of, at least part of, the pathogenesis of Alzheimer’s disease.

Introduction
Despite a significant increase in our understanding of the pathogenesis of Alzheimer’s disease (AD) over the past two decades, the therapeutic options are still very modest. Cholinesterase inhibitors and the N-methyl-D-aspartate receptor agonists currently available have a modest clinical effect but do not intervene with the underlying pathophysiology [1]. The ultimate aim of AD therapy is to stop or slow down the underlying disease process.

Recently the first two large trials with drugs that may slow disease progression have been published: a phase 2, passive immunization trial with bapineuzumab; and a phase 3 trial with tarenflurbil, a modulator of γ-secretase. Both drugs supposedly interfere with β-amyloid (Ab) metabolism. Abnormalities in Ab processing are thought to be central in AD pathophysiology according to the amyloid cascade hypothesis. The mode of action of bapineuzumab is to remove aggregated Ab, while tarenflurbil decreases the production of the pathogenic Ab42 peptide. In the present commentary, we discuss the results of these trials and the implications for future therapy and insight into AD pathophysiology.

The amyloid cascade
The amyloid hypothesis has led to an understanding of the pathology of AD, and also provides a basis for novel drug development. This hypothesis suggests that increased Ab production and subsequent aggregation in limbic and association cortices leads to synaptic changes and causes deposition of Ab42 in diffuse plaques, which in turn causes microglial and astrocytic activation. As a result, altered neuronal homeostasis and oxidative injury lead to tangle formation, and eventually to neuronal and synaptic dysfunction and selective neuronal loss [2,3]. The most important implied prediction of the hypothesis is that reduction of Ab aggregation would ameliorate AD symptoms.

Three methods for intervening in the amyloid cascade have thus far been tested in clinical trials: active immunization, passive immunization, and modulation of γ-secretase [4,5]. In this light we shall discuss the two recent clinical trials mentioned above: the phase 2 trial with bapineuzumab, and the phase 3 trial with tarenflurbil.

Bapineuzumab
Bapineuzumab is a humanized anti-Ab monoclonal antibody. Preclinical passive immunotherapy studies with monoclonal anti-Ab antibodies in a mouse model of AD showed antibody binding to Ab plaques, reduction in Ab plaque burden, and reversal of memory defects [6,7]. Bapineuzumab is directed against the N-terminus of Ab and is hypothesized to bind to Ab in the brain and to facilitate its removal.
The recently published phase 2 multiple-ascending-dose trial in mild to moderate AD tested the safety and efficacy of bapineuzumab [8]. Two hundred and thirty-four AD patients were randomly assigned to intravenous bapineuzumab (n = 124) or to placebo (n = 110) in four dose cohorts (0.15, 0.5, 1.0, or 2.0 mg/kg). Patients received six infusions, 13 weeks apart, with final assessments 18 months later. The primary efficacy analysis compared treatment differences within dose cohorts on the Alzheimer’s Disease Assessment Scale for Cognition and on the Disability Assessment for Dementia. No significant differences were found in the primary efficacy analysis.

Exploratory analyses, however, showed potential treatment differences on cognitive and functional endpoints in study completers and apolipoprotein E (APOE) ε4 noncarriers. In this subgroup, subjects on active treatment showed 5 points less decline on the Alzheimer’s Disease Assessment Scale for Cognition after 78 weeks compared with placebo. A safety concern was the occurrence of reversible vasogenic edema, detected on brain magnetic resonance imaging in 10% of the bapineuzumab-treated patients. Vasogenic edema was more frequent in APOE ε4 carriers, which may suggest that vasogenic edema is related to vascular amyloid burden since APOE ε4 carriers show more vascular amyloid deposition.

The potential treatment differences in the exploratory analyses have led to the evaluation of bapineuzumab in a phase 3 trial that started in December 2007, which will take possible treatment differences by APOE ε4 status into consideration. Meanwhile, a recent publication showed that treatment with bapineuzumab for 78 weeks reduced fibrillar amyloid burden in subjects with AD, shown by Pittsburgh compound B positron emission tomography (PiB-PET) [9].

Tarenflurbil
Tarenflurbil is a modulator of the activity of γ-secretase, and may for that reason act as an Aβ42 lowering agent. In mouse models of AD, tarenflurbil prevents learning and memory deficits and reduces Aβ42 brain concentrations [10]. In an earlier phase 2 trial in 210 AD patients, mildly affected patients (baseline mini-mental state examination 20 to 26), who received 800 mg tarenflurbil twice per day, had lower rates of decline in activities of daily living and global function compared with subjects who received placebo [11].

These results led to a large multicentre, phase 3, randomized, double-blind, placebo-controlled trial for the evaluation of the efficacy, safety, and tolerability of tarenflurbil in 1,684 subjects with mild AD (mini-mental state examination 15 to 26) [12]. Initially, patients were assigned to treatment with tarenflurbil at doses of either 400 or 800 mg twice daily or placebo. After an analysis of phase 2 data indicated that subjects had the strongest response to 800 mg tarenflurbil twice daily, however, the 400 mg dose was ended. The main outcome measures were the change from baseline to 18 months score on the Alzheimer’s Disease Assessment Scale for Cognition and on the Alzheimer’s Disease Cooperative Study – Activities of Daily Living scale. Tarenflurbil had no beneficial effect on the primary or secondary outcomes. The APOE genotype had no effect on treatment response. The tarenflurbil group had a small increase in frequency of dizziness, anemia, and infections.

Discussion
What have these two trials taught us? The bapineuzumab trial showed that intravenous administration of the serial bapineuzumab doses is feasible and, as long as the possible occurrence of vasogenic edema is monitored, is relatively safe. The positron emission tomography substudy provided the suggestion that bapineuzumab indeed reduces amyloid load in vivo. The lack of effect on the primary endpoint of the trial may be due to the fact that, as the authors point out, it was underpowered to show small differences in efficacy. Indeed, a larger sample size would have increased the ability to detect statistically significant differences, but this does not alter the notion that clinical effects may still be small and of limited relevance. In the case of the tarenflurbil trial, it is possible that the dose of 800 mg twice daily was still too low. The discrepant findings between the phase 2 subgroup analyses and the phase 3 study strongly caution against apparent overinterpretation of post hoc analyses.

The findings may also have implications for the amyloid hypothesis. First, it is possible that the relation between amyloid processing and AD is modified by the APOE genotype, and in this respect it will be interesting to see how a possible treatment effect may differ by APOE ε4 status in the new phase 3 bapineuzumab study. It stresses again how important APOE is in several aspects of AD [13,14].

Second, as reduction of Aβ42 was not effective and removal of aggregated Aβ had a limited effect, other Aβ species may be the main toxic agent in AD or the AD pathology may not depend on Aβ. Alternative models for AD pathophysiology may better explain how accumulation of Aβ42 leads to tangle formation, and why tangle formation is closer to neuronal cell death than amyloid accumulation [2].

Third, reduction of Aβ production or removal of Aβ may not be successful in patients who already have a substantial amyloid burden if the cascade becomes independent of amyloid burden once Aβ42 accumulation has set off an irreversible chain of events.

Finally, the amyloid hypothesis neglects the role of cerebrovascular damage, which is typically comorbid in
older patients with AD, and may be a crucial cofactor in causing neurodegeneration and may interact with the pathology of AD [15]. Cerebrovascular damage is a factor that may have to be taken into account when developing new therapeutic strategies for AD.

**Abbreviations**

Aβ, β-amyloid; AD, Alzheimer’s disease; APOE, apolipoprotein E.

**Competing interests**

NPD has a senior fellowship at the Alzheimer Centre VUMc partly supported by Vereniging AEGON. PJV is the recipient of a grant award from Bristol-Myers Squibb and is a consultant to Elan, Wyeth, Bristol-Myers Squibb, Myriad Pharmaceuticals and Danone Research. PS has consulted for Elan-Wyeth, Bristol-Myers Squibb and is a consultant to Elan, Wyeth, Bristol-Myers Squibb, Myriad Pharmaceuticals and Danone Research.

**Acknowledgements**

The study was in part funded by the European Commission within the sixth framework programme (LSHB-2007-037670, to PJV).

**Author details**

1. Alzheimer Center, VU University Medical Center, Boelelaan 1118, Amsterdam, The Netherlands. 2. Alzheimer Centre, School for Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, The Netherlands.

**Published: 9 April 2010**

**References**

1. Scarpi E, Scheltens P, Feldman H: Treatment of Alzheimer’s disease: current status and new perspectives. Lancet Neurol 2003, 2:539-547.

2. Hardy J: The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal. J Neurochem 2009, 110:1129-1134.

3. Selkoe DJ: Alzheimer disease: mechanistic understanding predicts novel therapies. Ann Intern Med 2004, 140:627-638.

4. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Granger JM: Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005, 64:1553-1562.

5. Schenk D, Games D, Seubert P: Potential treatment opportunities for Alzheimer’s disease through inhibition of secretases and Aβ immunization. J Mol Neurosci 2001, 17:259-267.

6. Bard F, Canon C, Barboun R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vazquez N, Weiss K, Welch R, Seubert P, Schenk D, Yednock T: Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000, 6:916-919.

7. Dodart JC, Bales KR, Gannon KS, Greene SJ, DelMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM: Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer’s disease model. Nat Neurosci 2002, 5:452-457.

8. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Muñard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M: A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009, 73:2061-2070.

9. Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, Rodríguez-Martínez de Liano S, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M: 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010, 9:363-372.

10. Kukar T, Prescott S, Eriksen JL, Holloway V, Murphy H, Koo EH, Golde TE, Nicolle MM: Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci 2007, 8:4.

11. Wilcock GK, Black SE, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA: Efficacy and safety of tarenflurib in mild to moderate Alzheimer’s disease: a randomised phase II trial. Lancet Neurol 2008, 7:483-493.

12. Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH: Effect of tarenflurib on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 2009, 302:2557-2564.

13. Kester MR, Blankenstein MA, Bouwman FH, van Elk EJ, Scheltens P, van der Flier WM: CSF biomarkers in Alzheimer’s disease and controls: associations with APOE genotype may be modified by age. J Alzheimers Dis 2009, 16:601-617.

14. Van der Flier WM, Schoonenboom SNM, Pijnenburg YAL, Fox NC, Scheltens P: The effect of APOE genotype on clinical phenotype in Alzheimer’s disease. Neurology 2006, 67:526-527.

15. De Leeuw F-E, Korf E, Barkhof F, Scheltens P: White matter lesions are associated with progression of medial temporal lobe atrophy in Alzheimer disease. Stroke 2006, 37:2248-2252.